Welcome to our dedicated page for AdaptHealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
Lundberg Theodore B. reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. director Theodore B. Lundberg received a grant of 18,999 restricted stock units of common stock on June 24, 2026. These units will be settled in common stock upon vesting. After this award, he directly holds a reported total of 892,495 shares.
AdaptHealth Corp. director Dale B. Wolf reported a compensation-related equity award and updated holdings. He received 18,999 shares of common stock as a grant or award, at a stated price of $0.00 per share, structured as restricted stock units that will settle in common stock upon vesting. After this grant, he directly holds 123,234 shares. Separately, 14,000 shares are held indirectly by the Dale B. Wolf Generation Skipping Trust, for which he is the investment manager. No option exercises, open-market buys, or sales are shown in this filing, making the activity primarily a routine equity compensation update and ownership report.
SAMET KENNETH A reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. director Kenneth A. Samet reported two stock awards of common shares. On June 24, he received 6,070 shares at a reference price of $9.89 per share, bringing that holding line to 25,069 shares. He also received 18,999 restricted stock units at no cost, which will be settled in common stock upon vesting, with 18,999 shares shown as held after that award. These are compensation-related grants, not market purchases or sales.
AdaptHealth Corp. director Kenneth A. Samet filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director of the company and does not report any stock transactions or derivative positions at this time.
AdaptHealth Corp. reported the results of its annual stockholder meeting held via live audio webcast. A quorum was present, with 120,652,493 common shares represented, accounting for 88.67% of the voting power entitled to vote.
Stockholders elected nine directors to one-year terms, with each nominee receiving strong majority support. They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation paid to the company’s named executive officers.
AdaptHealth Corp. Chief Commercial Officer Russell E. Schuster III sold 11,275 shares of Common Stock on June 1, 2026 at $10.06 per share in an open-market transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on March 2, 2026.
After this transaction, he directly holds 136,538 shares of AdaptHealth Common Stock, indicating that the sale represents only a portion of his overall stake.
AdaptHealth Corp. filed an amended report to correct the Date of Report for its earlier disclosure about appointing Daniel McFadden as Chief Operating Officer and to add his final compensation terms. The board’s compensation committee raised his annual base salary from $410,000 to $550,000, retroactive to the May 4, 2026 appointment date, and kept his target annual bonus at 100% of base salary, pro-rated for 2026. He also received a one-time restricted stock unit grant valued at $464,110, with half vesting annually over three years and half vesting between 0% and 200% based on relative total shareholder return over a three-year performance period beginning on February 1, 2026.
AdaptHealth Corp. reported that Chief Operating Officer Daniel Edward McFadden received an equity award in the form of restricted stock units. On the transaction date, he acquired 20,134 shares of Common Stock at no cash cost as a grant, increasing his direct holdings to 103,376 shares after the award. The footnote explains that these shares are restricted stock units that will be settled in common stock when they vest, meaning he does not receive all shares immediately but over time as vesting conditions are met.